Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
CASC's Cash to Debt is ranked higher than
100% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: 56.38 vs. CASC: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CASC' s Cash to Debt Range Over the Past 10 Years
Min: 5.92  Med: 170.56 Max: No Debt
Current: No Debt
Interest Coverage No Debt
CASC's Interest Coverage is ranked higher than
100% of the 364 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CASC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CASC' s Interest Coverage Range Over the Past 10 Years
Min: 976.29  Med: 9999.50 Max: 9999.99
Current: No Debt
976.29
9999.99
F-Score: 4
Z-Score: 21.45
M-Score: -1.62
WACC vs ROIC
19.65%
-133.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -41.53
CASC's ROE (%) is ranked lower than
57% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. CASC: -41.53 )
Ranked among companies with meaningful ROE (%) only.
CASC' s ROE (%) Range Over the Past 10 Years
Min: -163.15  Med: -64.90 Max: 43.53
Current: -41.53
-163.15
43.53
ROA (%) -36.52
CASC's ROA (%) is ranked lower than
59% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. CASC: -36.52 )
Ranked among companies with meaningful ROA (%) only.
CASC' s ROA (%) Range Over the Past 10 Years
Min: -80.5  Med: -50.43 Max: 23.29
Current: -36.52
-80.5
23.29
ROC (Joel Greenblatt) (%) -2045.38
CASC's ROC (Joel Greenblatt) (%) is ranked lower than
70% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -356.62 vs. CASC: -2045.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CASC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3364.41  Med: -2040.51 Max: 635.37
Current: -2045.38
-3364.41
635.37
EBITDA Growth (3Y)(%) 92.10
CASC's EBITDA Growth (3Y)(%) is ranked higher than
97% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.10 vs. CASC: 92.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CASC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -60  Med: -8.30 Max: 92.1
Current: 92.1
-60
92.1
EPS Growth (3Y)(%) 74.00
CASC's EPS Growth (3Y)(%) is ranked higher than
96% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CASC: 74.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CASC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -56.1  Med: -8.50 Max: 74
Current: 74
-56.1
74
» CASC's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with CASC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:INSM, NAS:PACB, NAS:ANIP, NAS:MACK, NAS:CERS, NAS:INO, NAS:NTLA, OTCPK:GNFTF, NAS:ATRA, OTCPK:IPHYF, NAS:CORT, OTCPK:SNBIF, OTCPK:BPMUF, NAS:XNCR, NAS:ANIK, NAS:FOLD, OTCPK:BIESF, NAS:ZIOP, NAS:DVAX, NAS:KERX » details
Traded in other countries:3O6.Germany,
Oncothyreon Inc is a clinical-stage biopharmaceutical company. It develops and commercialize synthetic vaccines & small molecules that treat the lives & outcomes of cancer patients.

Oncothyreon Inc was incorporated on September 7, 2007. The Company is a clinical-stage biopharmaceutical company that develops therapeutic products for the treatment of cancer. Its cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. The Company's cancer vaccine product candidate, tecemotide, formerly known as L-BLP25 or Stimuvax, is being evaluated for the treatment of non-small cell lung cancer, or NSCLC. It has granted license to Merck KGaA of Darmstadt, Germany, or Merck KGaA, for the development, manufacture and commercialization of tecemotide. The Company is also conducting Phase 1 trial for ONT-10, a cancer vaccine. The Company's pipeline of products includes immunotherapies and small molecules. The Company currently outsources the manufacturing of drug substances and drug products for all of its products in clinical development. As of December 31, 2013 the Company owned approximately 25 U.S. patents and patent applications. It competes with pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations which are developing various approaches to cancer therapy. In addition to regulations in the United States, the Company will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its product candidates.

Top Ranked Articles about Cascadian Therapeutics Inc

Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics Klarman takes 18 percent of cancer treatment developer as FDA fast-tracks product
Seth Klarman (Trades, Portfolio) continues to top weight his portfolio with outsized stakes in health care and pharmaceutical companies. June 30, he bought 18.5% of a company designing a treatment for breast cancer. Read more...
Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics Company has zero debt and is trading close to a 5-year low
Seth Klarman (Trades, Portfolio) purchased 25 million shares in biotechnology company Cascadian Therapeutics Inc. (NASDAQ:CASC) on June 30. Klarman paid 94 cents per share in a deal that had a 0.34% impact on his portfolio. Read more...

Ratios

vs
industry
vs
history
P/B 1.47
CASC's P/B is ranked higher than
82% of the 1024 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. CASC: 1.47 )
Ranked among companies with meaningful P/B only.
CASC' s P/B Range Over the Past 10 Years
Min: 0.74  Med: 4.10 Max: 23.59
Current: 1.47
0.74
23.59
EV-to-EBIT 0.80
CASC's EV-to-EBIT is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 22.27 vs. CASC: 0.80 )
Ranked among companies with meaningful EV-to-EBIT only.
CASC' s EV-to-EBIT Range Over the Past 10 Years
Min: -1611.1  Med: -2.10 Max: 10.1
Current: 0.8
-1611.1
10.1
EV-to-EBITDA 0.81
CASC's EV-to-EBITDA is ranked lower than
99.99% of the 304 Companies
in the Global Biotechnology industry.

( Industry Median: 18.12 vs. CASC: 0.81 )
Ranked among companies with meaningful EV-to-EBITDA only.
CASC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -8605.5  Med: -2.20 Max: 9.8
Current: 0.81
-8605.5
9.8
Current Ratio 8.83
CASC's Current Ratio is ranked higher than
72% of the 903 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. CASC: 8.83 )
Ranked among companies with meaningful Current Ratio only.
CASC' s Current Ratio Range Over the Past 10 Years
Min: 1.67  Med: 11.89 Max: 36.71
Current: 8.83
1.67
36.71
Quick Ratio 8.83
CASC's Quick Ratio is ranked higher than
74% of the 903 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. CASC: 8.83 )
Ranked among companies with meaningful Quick Ratio only.
CASC' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 11.89 Max: 36.71
Current: 8.83
0.95
36.71

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.26
CASC's Price/Net Cash is ranked higher than
66% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 4.94 vs. CASC: 3.26 )
Ranked among companies with meaningful Price/Net Cash only.
CASC' s Price/Net Cash Range Over the Past 10 Years
Min: 1.04  Med: 5.43 Max: 38.63
Current: 3.26
1.04
38.63
Price/Net Current Asset Value 3.08
CASC's Price/Net Current Asset Value is ranked higher than
68% of the 829 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. CASC: 3.08 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CASC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.91  Med: 5.18 Max: 38
Current: 3.08
0.91
38
Price/Tangible Book 2.90
CASC's Price/Tangible Book is ranked higher than
60% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. CASC: 2.90 )
Ranked among companies with meaningful Price/Tangible Book only.
CASC' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.84  Med: 4.64 Max: 73.64
Current: 2.9
0.84
73.64
Earnings Yield (Greenblatt) (%) 125.00
CASC's Earnings Yield (Greenblatt) (%) is ranked lower than
75% of the 1104 Companies
in the Global Biotechnology industry.

( Industry Median: -9.68 vs. CASC: 125.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CASC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 9.9  Med: 92.80 Max: 6723.4
Current: 125
9.9
6723.4

More Statistics

EPS (TTM) $ -0.40
Beta2.41
Short Percentage of Float6.05%
52-Week Range $0.82 - 3.89
Shares Outstanding (Mil)94.96

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $)
EPS ($) -0.38 -0.43 -0.43
EPS w/o NRI ($) -0.38 -0.43 -0.43
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:CASC

Headlines

Articles On GuruFocus.com
Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics as Price Declines Jul 12 2016 
Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics Jul 11 2016 
Value Betting with Special Situations: Lessons from the World of Gambling Mar 05 2013 
Cubist Pharmaceutical - Acutely Aware May 09 2010 

More From Other Websites
Technical Updates on Industrial Goods Sector Equities on CEMEX, 3M Company, Cascadian Therapeutics,... Jul 18 2016
Coverage of Top Gainers SAGE Therapeutics, Seagate Technology, and Cascadian Therapeutics Jul 13 2016
Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics as Price Declines Jul 11 2016
Cascadian Therapeutics Inc. (CASC): Billionaire Seth Klarman’s Baupost Group Reports New Stake Jul 11 2016
Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics Jul 11 2016
Cascadian Therapeutics Receives ONT-380 Fast Track Designation from FDA for the Treatment of... Jun 29 2016
CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 29 2016
Cascadian Therapeutics Receives ONT-380 Fast Track Designation from FDA for the Treatment of... Jun 29 2016
CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Jun 28 2016
Cascadian Therapeutics Announces Exercise of Underwriters' Over-Allotment Option and Closing of... Jun 28 2016
Cascadian Therapeutics (CASC) Jumps: Stock Rises 10.4% Jun 24 2016
CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Jun 23 2016
Cascadian Therapeutics Prices $41.8 Million Concurrent Offerings of Common Stock and Series D... Jun 23 2016
Cascadian Therapeutics Prices $41.8 Million Concurrent Offerings of Common Stock and Series D... Jun 23 2016
Cascadian Therapeutics Announces Proposed Public Offering Jun 22 2016
Cascadian Therapeutics Announces Proposed Public Offering Jun 22 2016
Biotech Stock Mailbag: Cascadian Therapeutics, Global Blood Therapeutics, Bad Favus Jun 20 2016
CASCADIAN THERAPEUTICS, INC. Financials Jun 16 2016
Cascadian Therapeutics (Nasdaq: CASC) to Ring The Nasdaq Stock Market Closing Bell Jun 14 2016
Cascadian Therapeutics (Nasdaq: CASC) to Ring The Nasdaq Stock Market Closing Bell Jun 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)